Rifabutin

證據等級: L5

預測適應症: 10 個

Rifabutin: From MAC Prophylaxis in AIDS to HIV Infectious Disease

One-Sentence Summary

Rifabutin (Mycobutin®) is a rifamycin-class antibiotic internationally approved for prevention and treatment of Mycobacterium avium complex (MAC) bacteremia in AIDS/HIV patients, though currently not registered in the Philippines. The TxGNN model predicts it may be effective for HIV Infectious Disease broadly, with 29 clinical trials and 20 publications currently supporting this direction. The evidence level is L1, underpinned by multiple completed Phase 3 RCTs, and FDA/EMA have already approved this indication under the Mycobutin® brand.

Quick Overview

Item	Content
Original Indication	Not registered in Philippines; internationally approved for MAC prophylaxis/treatment in HIV/AIDS patients (Mycobutin®)
Predicted New Indication	HIV Infectious Disease
TxGNN Prediction Score	99.88%
Evidence Level	L1
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Philippines regulatory database. Based on known information, Rifabutin belongs to the rifamycin class of antibiotics and acts as a bacterial RNA polymerase inhibitor, binding to the β-subunit of RNA polymerase (rpoB) to block transcription in mycobacterial species. It demonstrates particularly high potency against Mycobacterium avium complex (MAC) — the most common opportunistic pathogen causing bacteremia in severely immunocompromised HIV patients with CD4 counts below 200 cells/mm³. Multiple landmark trials in the 1990s established its efficacy for MAC prophylaxis and treatment, leading to FDA and EMA approval as Mycobutin®.

Beyond MAC, rifabutin plays a critical role in HIV/TB coinfection management. HIV-infected patients have an annual TB reactivation risk 10 times higher than HIV-negative individuals, and treating both infections simultaneously requires careful consideration of drug-drug interactions. Rifabutin is a significantly weaker inducer of CYP3A4 compared to rifampicin, making it the preferred rifamycin when patients are receiving protease inhibitor (PI)- or NNRTI-based antiretroviral therapy. This pharmacokinetic advantage means rifabutin can be safely co-administered with most antiretroviral regimens where rifampicin would cause unacceptable reductions in ART drug exposure.

The TxGNN prediction therefore captures a biologically coherent relationship: rifabutin’s role spans MAC prophylaxis, MAC treatment, and TB co-treatment — all within the HIV infectious disease framework. The knowledge graph nodes linking rifabutin to HIV reflect this established clinical reality, which is why the evidence base is exceptionally strong (L1) and the prediction score approaches 100%.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00002267	NA	Completed	750	Double-blind, placebo-controlled RCT assessing rifabutin monotherapy for prevention of MAC bacteremia in AIDS patients with CD4 ≤ 200; primary endpoints include incidence of MAC and survival benefit
NCT00002101	Phase 3	Completed	450	Three-arm RCT comparing clarithromycin/ethambutol with placebo, rifabutin 300 mg, or rifabutin 450 mg for MAC bacteremia in AIDS; primary endpoint: ≥2-log CFU reduction sustained through 16 weeks
NCT00001030	Phase 3	Completed	1,100	Prospective RCT comparing clarithromycin alone vs. rifabutin alone vs. combination for prevention of MAC bacteremia in HIV patients with CD4 ≤ 100 cells/mm³; also captured survival and quality of life
NCT00001047	Phase 3	Completed	400	Open-label RCT comparing clarithromycin + ethambutol + rifabutin vs. clarithromycin + ethambutol + clofazimine at two clarithromycin doses for disseminated MAC in AIDS patients
NCT00002122	Phase 3	Completed	720	RCT evaluating azithromycin and rifabutin alone or combined for MAC prevention; secondary arm assessed daily vs. weekly fluconazole for deep fungal infection prevention
NCT00001995	NA	Completed	200	Double-blind RCT of rifabutin-containing regimen to eradicate or reduce MAC organisms in AIDS patients; assessed symptom improvement and survival outcomes
NCT03478033	NA	Unknown	230	Prospective multicenter cohort comparing standard rifampicin vs. rifabutin-based TB treatment in HIV/AIDS patients with pulmonary TB; evaluates antiviral efficacy and drug-drug interactions with ART
NCT00651066	Phase 2	Completed	47	Phase II PK trial in Vietnam evaluating rifabutin as a rifampicin replacement in HIV/TB coinfected patients on various ART regimens; supports rifabutin as preferred rifamycin with PI/NNRTI-based ART
NCT01601626	Phase 2	Terminated	71	Phase 2b RCT comparing double-dose LPV/r + rifampin vs. standard-dose LPV/r + rifabutin ± raltegravir in HIV-1 patients requiring PI-based ART and active TB treatment; terminated early, data limited
NCT00810446	N/A	Completed	72	Japanese regulatory post-marketing commitment surveillance of Mycobutin® in HIV-infected patients; collected real-world safety data including unknown adverse reactions over 9 years

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23828580	2013	Systematic Review	Cochrane Database Syst Rev	Meta-analysis comparing rifamycins (rifampicin, rifabutin, rifapentine) vs. isoniazid for TB prevention in HIV-negative high-risk individuals; supports rifabutin as an effective LTBI prophylaxis option with shorter treatment duration and comparable completion rates
25404581	2014	Systematic Review	Evidence-Based Child Health	Cochrane review update on rifamycins vs. isoniazid for TB prophylaxis; reaffirms rifabutin efficacy in latent TB prevention, supporting use as an isoniazid alternative
33294914	2021	Cohort/PK Study	J Antimicrob Chemother	PK and safety of rifabutin in HIV/TB coinfected children receiving lopinavir/ritonavir-based second-line ART; highlights neutropenia risk and limited pediatric dosing data
31139825	2019	Cohort	J Antimicrob Chemother	Safety and efficacy evaluation of rifabutin in HIV/TB coinfected children on PI-based ART; treatment-limiting neutropenia in 2/6 patients underscores need for hematologic monitoring
25281400	2015	PK Study	J Antimicrob Chemother	Short-term safety and pharmacokinetics of rifabutin with lopinavir/ritonavir in young HIV-infected children (≤5 years); characterizes DDI profile to guide pediatric dosing strategies
28233512	2017	Review	Microbiol Spectrum	Comprehensive review of TB-HIV coinfection; describes bidirectional disease synergy and positions rifabutin as the recommended rifamycin for patients on PI-based ART regimens
21726477	2009	Review	BMJ Clin Evid	Evidence-based review on treating TB in HIV patients; establishes rifabutin as preferred over rifampicin when patients receive PI-based ART, based on superior DDI profile
7736687	1995	PK Review	Clin Pharmacokinet	Landmark pharmacokinetics review of rifabutin; characterizes oral bioavailability (~20%), extensive tissue distribution, and CYP3A4 induction profile compared to rifampicin
40310456	2025	Review	PNAS	Review of next-generation rifamycins; discusses rifabutin’s current role in NTM infections and its CYP3A4 induction profile relative to newer rifamycin analogs under development
9459473	1998	Observational	JAMA	HIV Outpatient Study (HOPS) showing possible effectiveness of clarithromycin + rifabutin as chemoprophylaxis for cryptosporidiosis in HIV disease, suggesting additional opportunistic infection benefit

Philippines Market Information

Rifabutin currently has no registered products with the Philippine FDA. No license records are available for any brand or formulation in the Philippines.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 3 RCTs (NCT00002101 n=450, NCT00001030 n=1,100, NCT00001047 n=400, NCT00002122 n=720) provide L1 evidence supporting rifabutin’s efficacy in HIV-associated MAC disease, and the drug is already FDA- and EMA-approved as Mycobutin®. The Philippines currently has no registered product, but the international evidence base is exceptionally mature and the clinical need in HIV-infected patients is well-established.

To proceed, the following is needed:

Philippine FDA registration application, including submission of existing international approval dossiers (FDA USA, EMA) for bridging review
Full prescribing information (package insert) with complete warnings, contraindications, and drug interaction listings — currently unavailable for this evidence pack
Mechanism of action documentation from DrugBank or equivalent source (currently a high-severity data gap)
Drug-drug interaction management protocol for co-administration with antiretroviral agents, particularly protease inhibitors (lopinavir/ritonavir, darunavir/ritonavir) and integrase inhibitors (dolutegravir, cabotegravir)
Safety monitoring plan addressing known rifabutin toxicities: ophthalmologic monitoring for uveitis (especially when combined with clarithromycin or azole antifungals) and hematologic monitoring (CBC for neutropenia/thrombocytopenia)
Identification of a Philippine distribution partner and assessment of cold-chain/specialty pharmacy infrastructure for access through HIV treatment programs (e.g., Pilipinas CEAP, DOH HIV treatment hubs)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.